Bitcoin

In a market already gripped by extreme fear (Fear & Greed 25) and bearish sentiment, non-crypto news like this is largely noise. However, the broader narrative of 'biohacking' and longevity is gaining traction in Web3, with projects like VitaDAO and others exploring decentralized science (DeSci). This study could indirectly reinforce interest in health-related crypto verticals, but the effect is negligible in the current macro environment.

Study finds chewing sugary gum after consuming nitrate-rich vegetables or beetroot juice increases nitrite production and temporarily lowers blood pressure.

Chewing Sugary Gum After Beetroot Juice Lowers Blood Pressure, Study Finds – But Sugar Raises Questions

While the market panics in extreme fear, a study on gum and beetroot juice reveals the power of overlooked micro-interventions – hinting that crypto's next move may come from a forgotten corner.

This article serves as a proxy for the ongoing debate between hype and evidence across both health and financial markets. For crypto, it mirrors the pattern where narrative outpaces fundamental adoption—think DeFi yields or meme coins. The timing during extreme fear (F&G=9) suggests that institutional and retail participants may become even more risk-averse, delaying capital rotation into risk-on assets.

Nature publishes a commentary noting that enthusiasm for unregulated peptide injections, the hottest wellness trend, has outpaced scientific evidence.

Nature's Peptide Warning: Scientific Skepticism Could Spill Over Into Crypto Health Tokens

Nature's Peptide Warning Sets a Precedent: Unregulated Crypto Health Tokens Could Be Next on the Chopping Block

The article underscores the ongoing disconnect between hype and evidence in the wellness industry, a dynamic that occasionally parallels narratives in crypto (e.g., speculative health tokens). However, given the current macro environment (Fear & Greed at 27, BTC dominance high), capital is rotating into Bitcoin as a safe haven, not into niche sectors like biohacking.

Nature published an article on 20 May 2026 examining the scientific basis of red light therapy and photobiomodulation, highlighting the gap between commercial devices and clinical evidence.